AstraZeneca PLC (AZN)vsNano X Imaging Ltd (NNOX)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
NNOX
Nano X Imaging Ltd
$1.71
0.00%
HEALTHCARE · Cap: $129.44M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 451010% more annual revenue ($58.74B vs $13.02M). AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
NNOX
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+53.7%
Fair Value
$4.84
Current Price
$1.71
$3.13 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 24.0% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : NNOX
The strongest argument for NNOX centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 24.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : NNOX
The primary concerns for NNOX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a value stock while NNOX is a growth play — different risk/reward profiles.
NNOX carries more volatility with a beta of 1.38 — expect wider price swings.
NNOX is growing revenue faster at 24.0% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 32/100), backed by strong 17.4% margins. NNOX offers better value entry with a 53.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Nano X Imaging Ltd
HEALTHCARE · MEDICAL DEVICES · USA
Nano-X Imaging Ltd., a development-stage company, develops, produces and markets digital X-ray source technology for the medical imaging industry globally. The company is headquartered in Neve Ilan, Israel.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?